BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Topiroxostat

Summary

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]

Topiroxostat
Clinical data
Trade namesTopiloric, Uriadec
ATC code
  • None
Legal status
Legal status
  • Approved in Japan
Identifiers
  • 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile
CAS Number
  • 577778-58-6
PubChem CID
  • 5288320
ChemSpider
  • 4450517
UNII
  • 0J877412JV
CompTox Dashboard (EPA)
  • DTXSID80206462 Edit this at Wikidata
Chemical and physical data
FormulaC13H8N6
Molar mass248.249 g·mol−1
3D model (JSmol)
  • Interactive image
  • C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
  • InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
  • Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]

References edit

  1. ^ a b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. {{cite journal}}: Cite journal requires |journal= (help)
  2. ^ Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.